48 completed, 3 unknown, 2 recruiting, 1 suspended. 26 Phase 3, 24 Phase 2, 5 Not applicable, 2 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 26 | Completed 25, Suspended 1 |
| Phase 2 | 24 | Completed 22, Recruiting 1, Unknown 1 |
| Not applicable | 5 | Completed 3, Recruiting 1, Unknown 1 |
| Phase 4 | 2 | Completed 1, Unknown 1 |
Follow Catalysis SL: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pre-habilitation Within ERAS Protocol for Gynecologic Oncology Surgery: The Pre_ERAS Study Ocoxin, Structured self-guided exercise - ERAS, Compliance | Not applicable | Recruiting | Aristotle University Of Thessaloniki | 100 | 2025-12-01 | 2025-10-07 |
| Efficacy of Carminal in Helicobacter Pylori Gastritis Carminal Oral solution, Placebo - H Pylori Gastritis, H Pylori Infection | Phase 2 | Recruiting | Catalysis SL | 80 | 2025-08-04 | 2025-09-17 |
| Effect and Safety of Ocoxin Oral Solution on the Quality of Life of Paediatric Patients With Advanced Stage Solid Tumours Ocoxin Oral solution - Advanced Cancer, Advanced Solid Tumor | Not applicable | Unknown | Catalysis SL | 40 | 2024-04-28 | 2024-04-12 |
| Evaluation Of The Efficacy Of The Combination Of GLIZIGEN® Oral Solution 1/Day And Vaginal Gel 1/Night For 2 Months In Patients With Cervical Intraepithelial Neoplasia Grade 1 (LSIL/CIN-1) Caused By High-Risk Human Papillomavirus (HPV-AR) Glizigen, Placebo - Papilloma Viral Infection, CIN1 | Phase 4 | Unknown | Catalysis SL | 120 | 2023-06-07 | 2024-02-07 |
| Evaluation of DEPREXIL in Patients With Clinical Depression Through Psychological and Neuroendocrine Assessment DEPREXIL - Depression, Post-COVID-19 Syndrome | Not applicable | Completed | Catalysis SL | 100 | 2022-11-01 | 2024-07-11 |
| Efficacy and Safety of Blue Cap for the Treatment of Atopic Dermatitis in Children Blue Cap Foam - Atopic Dermatitis, Atopic Dermatitis and Related Conditions | Phase 3 | Completed | Catalysis SL | 58 | 2022-03-15 | 2024-04-15 |
| Evaluation of Treatment With Viusid in Post-COVID-19 Syndrome Viusid Oral Solution, Placebo - Post-COVID-19 Syndrome, COVID-19 | Not applicable | Completed | Catalysis SL | 200 | 2022-02-15 | 2024-06-03 |
| The Effectiveness of Spermotrend Food Supplement in the Treatment of Male Infertility Spermotrend - Male Infertility, Benign Prostatic Hyperplasia | Phase 2 / Phase 3 | Completed | Catalysis SL | 150 | 2021-06-15 | 2023-03-28 |
| Evaluation of the Effectiveness of Therapy for Patients With Covid-19 Using Food Supplements Viusid + Asbrip Viusid and Asbrip, COVID-19 Standard Therapy - Covid19, COVID-19 Pneumonia | Not applicable | Completed | Catalysis SL | 80 | 2021-01-08 | 2022-04-13 |
| Efficacy and Safety of Viusid and Asbrip in Hospitalized Patients With Mild and Moderate COVID-19 Viusid, Asbrip, Standard Care - Covid19, Respiratory Disease | Phase 2 | Completed | Catalysis SL | 60 | 2020-11-09 | 2021-10-21 |
| Safety and Efficacy of Viusid and Asbrip in Hospitalized Patients Infected by SARS-Cov-2 With COVID-19 Viusid and Asbrip - Covid-19, Sars-CoV2 | Phase 2 | Completed | Catalysis SL | 60 | 2020-05-04 | 2021-01-08 |
| Efficacy and Safety of Renalof® in the Removal of Calculi Smaller Than 10 mm Located in the Reno-Ureteral Tract Renalof, Placebo - Renal Injury, Kidney Injury | Phase 2 | Completed | Catalysis SL | 155 | 2019-08-01 | 2021-01-06 |
| Evaluation Glizigen® and Ocoxin®-Viusid® in High-grade Cervical Intraepithelial Lesions Glizigen® + Ocoxin-Viusid® - Carcinoma, Neoplasia; Intraepithelial, Cervix | Phase 2 | Unknown | Catalysis SL | 62 | 2019-03-11 | 2024-02-07 |
| Evaluation of Ocoxin-Viusid® in Advanced Pancreatic Adenocarcinoma Ocoxin-Viusid® - Adenocarcinoma of the Pancreas, Pancreatic Cancer | Phase 2 | Completed | Catalysis SL | 30 | 2018-10-30 | 2023-03-28 |
| Evaluation of Ocoxin-Viusid® in Advanced or Metastatic Ovarian Epithelial Cancer Ocoxin-Viusid - Carcinoma, Ovarian Neoplasm | Phase 2 | Completed | Catalysis SL | 40 | 2018-10-25 | 2022-07-06 |
| Evaluation of Ocoxin®-Viusid® in Advanced Stomach Cancer and Gastric Esophagogastric Junction Ocoxin-Viusid® - Stomach Neoplasm, Gastrointestinal Neoplasms | Phase 2 | Completed | Catalysis SL | 45 | 2018-10-25 | 2024-02-07 |
| Evaluation of Ocoxin®-Viusid® in Metastatic Colorectal Adenocarcinoma Ocoxin-Viusid - Colorectal Neoplasm, Intestinal Neoplasms | Phase 2 | Completed | Catalysis SL | 40 | 2018-10-25 | 2024-02-07 |
| Evaluation of Obex® in Overweight and Obesity Obex, Placebo - Overweight and Obesity | Phase 3 | Completed | Catalysis SL | 160 | 2018-10-01 | 2021-10-21 |
| Evaluation of ONCOXIN® in Oral Mucositis, Appetite and Body Mass in Cancer Patients. Oncoxin® - Mucositis Oral | Phase 2 | Completed | Catalysis SL | 15 | 2017-11-01 | 2018-08-01 |
| Oncoxin® and Quality of Life in Cancer Patients ONCOXIN® - Gastric Cancer Stage II, Non-small Cell Lung Cancer Stage II | Phase 4 | Completed | Catalysis SL | 133 | 2017-11-01 | 2019-06-05 |
Showing 20 of 54. Sign in to see all of them.
COVID-19 (4) · Diabetes Mellitus (3) · Digestive System Diseases (3) · Digestive System Neoplasms (3) · Insulin Resistance (3) · Obesity (3) · Overweight (3) · Weight Loss (3) · Carcinoma (2) · Depression (2) · Diabetes Mellitus, Type 2 (2) · Endocrine Gland Neoplasms (2) · Endocrine System Diseases (2) · Gastrointestinal Diseases (2) · Gastrointestinal Neoplasms (2)
Viusid (13) · Ocoxin (8) · Dietary Supplements (3) · Cosmetics (2) · Standard of Care (1) · hydroquinone (1)
Cuba (39) · Colombia (2) · Kazakhstan (2) · Nicaragua (2) · Russia (2) · Serbia (2) · Spain (2) · Bulgaria (1) · Ecuador (1) · Greece (1) · Honduras (1)
Edelisa Moredo Romo, MD (2) · Eduardo Vilar Gomez, Ph.D (2) · Omara Lemus, MD (2) · Alfredo Abreu Daniel, PhD (1) · Consuelo Prado, Ph.D. (1) · Dimitrios C. Tsolakidis, MD, PhD (1) · Eduardo Cabrera, M.D., Ph.D. (1) · Eduardo Cabrera-Rode, PhD (1) · Fernanda Pastrana, MD (1)
PMID 17311621, PMID 19691668, PMID 20518086, PMID 22021873, PMID 31641390, PMID 33235733, PMID 35506389, PMID 36804035